Sacubitril-13C4 (hemicalcium salt)

Sacubitril-13C4 (hemicalcium salt) is a 13C-labeled and deuterium labeled Sacubitril hemicalcium salt. Sacubitril (AHU-377) hemicalcium salt is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696[1].

Product Specifications

Product Name Alternative

AHU-377-13C4 (hemicalcium salt)

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Neprilysin

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sacubitril-13c4-hemicalcium-salt.html

Solubility

10 mM in DMSO

Smiles

O=[13C]([13CH2][13CH2][13C]([O-])=O)N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@@H](C)C(OCC)=O.[0.5Ca2+]

Molecular Formula

C20 13C4H28Ca0.5NO5

Molecular Weight

434.49

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38 (10) :1689-700.; Voors AA, et al. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22 (8) :1041-7.; von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8 (1) :71-8.